Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that CEO Greg Divis will participate in a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17 at 10:40 a.m. ET. The event will be accessible via a live webcast on Avadel's Investor Relations website, along with an archived recording available for 90 days post-conference. Avadel focuses on innovative medications, with its lead drug candidate FT218 aimed at treating narcolepsy-related symptoms using proprietary drug delivery technology.

News Market Reaction – AVDL

+1.55%

+1.55% Session move

In the trading session that priced this news, AVDL gained 1.55%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at the Oppenheimer 32^nd Annual Healthcare Conference on Thursday, March 17 at 10:40 a.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

When is Avadel Pharmaceuticals participating in the Oppenheimer Healthcare Conference?

Avadel Pharmaceuticals will participate in the Oppenheimer 32nd Annual Healthcare Conference on March 17 at 10:40 a.m. ET.

Who will represent Avadel Pharmaceuticals at the conference?

CEO Greg Divis will represent Avadel Pharmaceuticals during the virtual fireside chat.

Where can I watch the Avadel Pharmaceuticals conference webcast?

The webcast will be available on Avadel's Investor Relations website at investors.avadel.com.

What is the focus of Avadel Pharmaceuticals?

Avadel Pharmaceuticals focuses on transforming medicines, particularly through innovative solutions like its lead drug candidate FT218 for narcolepsy.

How long will the conference recording be available?

The archived recording of the conference will be available for 90 days following the event.